SPY412.86+1.22 0.30%
DIA336.79-0.76 -0.23%
IXIC13,996.10+146.10 1.05%

BRIEF-Immatics Presents Data Update On Dose Escalation From Ongoing Actengine Cell Therapy Programs

· 03/17/2021 07:46
BRIEF-Immatics Presents Data Update On Dose Escalation From Ongoing Actengine Cell Therapy Programs

- Immatics NV 4A3.SG:

  • IMMATICS PRESENTS DATA UPDATE ON DOSE ESCALATION FROM ONGOING ACTENGINE® CELL THERAPY PROGRAMS

  • IMMATICS NV - ACTENGINE PRODUCT CANDIDATES WERE WELL TOLERATED. ALL ADVERSE EVENTS WERE TRANSIENT AND MANAGEABLE.

  • IMMATICS NV - NO DOSE-LIMITING TOXICITIES WERE OBSERVED IN PATIENTS TREATED WITH IMA201 AND IMA202

  • IMMATICS NV - ONE PATIENT RECEIVING IMA203 AT DOSE LEVEL 2 EXPERIENCED A DOSE LIMITING TOXICITY (DLT) AS DEFINED IN THE TRIAL PROTOCOL

Source text for Eikon: ID:nGNX97f5mv

Further company coverage: 4A3.SG


((Reuters.Briefs@thomsonreuters.com;))